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doi:10.1016/j.ejvs.2010.08.026Abstract Background: Randomised trials have failed todemonstratebenefit fromearly surgical
repair of small abdominal aortic aneurysm (AAA) comparedwith surveillance. This study aimed to
compare results afterendovascular aortic aneurysm repair (EVAR) or surveillance inAAA<5.5 cm.
Methods: Patients (50e79 years) with AAA of 4.1e5.4 cmwere randomly assigned, in a 1:1 ratio,
to receive immediate EVAR or surveillance by ultrasound and computed tomography (CT) and
repair only after a defined threshold (diameter 5.5 cm, enlargement >1 cm /year, symptoms)
was achieved. The main end point was all-cause mortality. Recruitment is closed; results at
a median follow-up of 32.4 months are here reported.
Results: Between 2004 and 2008, 360 patients (early EVAR Z 182; surveillance Z 178) were
enrolled. One perioperative death after EVAR and two late ruptures (both in the surveillance
group) occurred. At 54 months, there was no significant difference in the main end-point
rate [hazard ratio (HR) 0.76; 95% confidence interval (CI) 0.30e1.93; pZ 0.6] with KaplaneMeier
estimates of all-cause mortality of 14.5% in the EVAR and 10.1% in the surveillance group. Aneu-
rysm-relatedmortality, aneurysm rupture andmajormorbidity rateswere similar. KaplaneMeier
estimates of aneurysms growth5mmat 36monthswere 8.4% in the EVAR group and 67.5% in the
surveillance group (HR 10.49; 95% CI 6.88e15.96; p < 0.01). For aneurysms under surveillance,
the probability of delayed repair was 59.7% at 36 months (84.5% at 54 months). The probability
of receiving open repair at 36 months for EVAR feasibility loss was 16.4%.
Conclusion: Mortality and rupture rates in AAA <5.5 cm are low and no clear advantage was
shown between early or delayed EVAR strategy. However, within 36 months, three out of every
five small aneurysms under surveillance might grow to require repair and one out of every six
might lose feasibility for EVAR.58705419; fax: þ39 06 58704529.
gmail.com (P. Cao), plderango@gmail.com (P. De Rango).
end of the article.
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
14 P. Cao et al.Surveillance is safe for small AAA if close supervision is applied. Long-term data are needed to
confirm these results.
Clinical Trial Registration Information: This study is registered, NCT Identifier: NCT00118573.
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demonstrated that there is no advantage of surgery versus
surveillance in the treatment of patients with abdominal
aortic aneurysms (AAAs) in the diameter range of
4.1e5.5 cm.1e3
However, since then, there has been an increasing
application of endovascular aortic aneurysm repair (EVAR)
as a less-invasive alternative to open surgery.4e6 EVAR with
last-generation devices has been claimed to significantly
decrease the operative risks with respect to open surgery
and proposed as a potential choice for early treatment of
patients with small AAA to prevent the future risk of
rupture.5,6
Although the natural history of AAA is that of
a continuing growth, the rupture risk, at small aneurysm
size, may be so low that early EVAR may result in over-
treatment, exposing the patients to unnecessary risk of
early or late procedure-related complications.7,8 On the
other hand, there is the potential risk that surveillance
would miss unpredicted ruptures in small AAA.
The Comparison of surveillance versus Aortic Endog-
rafting for Small Aneurysm Repair study (CAESAR) is
a randomised multicentre trial that was launched to
compare early endovascular repair versus surveillance with
ultrasonography and computed tomography (CT) in the
treatment of aneurysms between 4.1 and 5.4 cm in diam-
eter. Midterm results are presented.
Methods
Detailed methods of the CAESAR trial have been previously
published.9 Briefly, recruitment began on 30 August 2004,
and ended on 31 December 2008 with 20 approved
participating European/Western Asian hospitals. Data
acquisition was stopped on 31 January 2010, for this report.
The trial was performed according to the CONsolidated
Standards of Reporting Trials (CONSORT) Statement
recommendations10 and registered at http://www.
clinicaltrials.gov with NCT Identifier: NCT00118573 (Study
ID Numbers ICMJE 384/03).
The study was approved by a central human rights
committee and the institutional review boards at each
participating centre. An independent data monitoring
committee reviewed the data at regular intervals. Trained
trial coordinators at every centre were responsible for
recruitment of patients and data collection. Data were
collected centrally at the main trial office based at the
Vascular Surgery Unit of Hospital S. Maria Misericordia,
University of Perugia, Perugia, Italy.
Study participants: patients
Eligible patients had an AAA of 4.1e5.4 cm in diameter,
50e79 years of age, AAA suitable for EVAR as evaluated byCT scan (performed within 3 months) and at least a 5-year
life expectancy.
Patients were excluded if they had severe co-morbidities
or a suprarenal/thoracic aorta 4.0 cm, needed urgent
repair, or were unable or unwilling to give informed consent
or follow the protocol.
Entry evaluation included demographics, co-morbidities,
medications, risk factors (defined according to the Society of
Vascular Surgeons/American Association for Vascular Surgery
(SVS/AAVS) reporting standards)11 and measurements of
various parameters from preoperative aortic imaging (e.g.,
aortic neck length and diameter) to assess the suitability for
EVAR.EVARsuitability beforeandafter randomisationwas left
at the discretion of the participating centre and based on CT
evaluation. CT measurements were mandatory to determine
aneurysm diameter and suitability for EVAR before random-
isation, as well as need for repair during follow-up. Diameter
of the aneurysm was defined on CT scan at the maximum
external cross-sectional measurement in any plane but
perpendicular to the vessel axis. The study included a central
review of all CT imaging morphology data (core lab analysis).
Anonymised records of patients with AAA 4.1e5.4 cm not
included in the trial were kept in a separate database and
reasons for exclusion recorded.
Participants: centres
The protocol specified that only centres performing both
endovascular and open aortic repair could be approved to
participate. For participation in the trial, individuals were
required to have: (1) a minimum yearly volume of 50 AAA
open or endovascular repairs, (2) performed at least 50
EVAR procedures in their experience and (3) provided track
record of all aortic procedures performed during the past
two years. Participating centres had to ensure high-quality
CT scan and ultrasonography studies in validated laborato-
ries by operators with documented experience in this field
and adherence with the rules of the trial until the
completion of the study.
Randomisation and masking
Randomisation was designed with equal probability (1:1
ratio) of assignment to either early EVAR or surveillance
by means of a computed-generated random-number list,
stratified by centre using a permuted block design and
carried online through the Internet. After eligibility verifi-
cation, allocated treatment was immediately available
from the website (www.caesarstudy.com) to authorised
accessed investigators.
Although patient assignment was necessarily unblinded,
outcome data by treatment group were available during
enrolment only to the biostatistician and data monitoring
committee.
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For patients assigned to early EVAR, the transluminal
introduction of an aortic endograft system needed to be
performed as soon as possible. To guarantee homogeneity
of results, a single model of device (Zenith AAA Endovas-
cular Graft; William Cook Europe, Bjaverskov, Denmark)
was allowed for EVAR throughout the duration of
enrolment.
Colour duplex ultrasound and plain X-ray of the abdomen
were required before discharge. Follow-up visits were
scheduled at 1 month and every 6 months thereafter, with
clinical and ultrasound examination. Plain X-ray and
contrast-enhanced CT scan were required yearly.
Patients assigned to the surveillance arm were seen
every 6 months with clinical and ultrasonography studies
and annual CT scan. Surveillance was continued until
either the patients died, or repair was assigned or the trial
ended. Repair was allowed only when the aneurysm grew
to 5.5 cm diameter in size, rapidly increased in diameter
(>1 cm/ year) or became symptomatic. Patients under
surveillance, who met one or more threshold criteria for
repair, were treated as soon as possible. EVAR was per-
formed if anatomical suitability was maintained; alter-
natively open surgery was chosen.
Ultrasonography was not used to define aneurysm
diameters but only to monitor aneurysm size and to assess
achievement of threshold criteria that needed CT
confirmation.
Outcome measures
The primary outcome measure was mortality from any
cause. Secondary outcomes included: (1) aneurysm-related
deaths (defined as any death caused directly or indirectly
by aneurysm rupture or aneurysm repair), (2) aneurysm
rupture, (3) perioperative (30 days or inpatient) or late
adverse events (defined according to the SVS/AAVS
reporting standards),11 (4) conversion to open repair, (5)
loss of treatment options (anatomical suitability for EVAR)
and (6) aneurysm growth rate.
Statistical analysis
We originally calculated that 740 patients (i.e., 370
patients per group) needed to be enrolled to detect a 5%
and a 15% difference in survival rates at 36 and 54 months,
respectively, between the early EVAR and the control
groups with a statistical power of 80% at the 5% significance
level. The values for the surveillance group were those
observed in the UK Small Aneurysm Trial Participants.13 To
reach this number, we planned a 2-year enrolment period
and an additional follow-up of 3 years, assuming 3% loss to
follow-up.
After 2 years of enrolment, on the basis of the observed
adverse events, it was estimated that more than 3000
patients were needed to be enrolled.
Consequently, the study was reconfigured to reflect
lower than planned enrolment rate and lower all-cause
mortality rate. Enrolment was continued for an additional 2
years and 4 months. Nevertheless, following a futilityanalysis (major outcome difference 1.4%), the Committee
stopped recruitment on 31 December 2008.
Primary analysis was by intention-to-treat. Outcomes
were given in absolute numbers and in cumulative inci-
dences. Rates of cumulative event after 36 and 54 months’
rates were calculated by the KaplaneMeier method to
compensate for patient dropouts and estimates between the
two randomisation groups were compared with the log-rank
and Wilcoxon tests. Interactions of covariate on outcome
were estimated with Cox proportional hazard regression
models and expressed as hazard ratios (HRs) with confidence
intervals (CIs), coefficient and standard errors. Covariates in
the Cox model were selected through stepwise regression
using the maximum partial likelihood ratio (enter 0.10;
remove 0.15). Variables were compared by using c2, Fisher’s
exact test, t-test and analysis of variance (ANOVA) when
appropriate. Mean with Standard Deviation (SD) and median
with interquartiles ranges (IQRs) were used to describe
continuous variables. Aneurysm growth over time in the two
groups was assessed with linear regression. P-values were
two-sided and P < 0.05 was considered statistically signifi-
cant. Statistical analyses were performed using BioMedical
Data Processing (BMDP) Statistical Software Package, version
2009 (Statistical Software Inc., Los Angeles, CA, USA).
The protocol originally specified publication of 54-month
results when available on all patients to ensure that short-
termpostoperative risks after early EVARwould be distanced
and balanced with the surveillance arm risks. Because of
important changes in survival and aneurysm growth noted
during the second year of follow-up, allowing higher than
expected repair rates in the surveillance arm, this plan was
amended to reveal midterm results of the trial in a report.
Role of the funding source
The trial was originally funded with a grant by Cook
Medical. In December 2006, the sponsorship withdrew.
Enrolment and follow-up fees for patients included in the
study after 1 January 2007 were not paid by any sponsorship
and the trial continued as a full spontaneous research
unfunded trial. However, study design, data collection,
data analysis, data interpretation and the writing of the
report were at all times conducted independently from
the sponsor. The corresponding author had full access to all
the data and had final responsibility for the decision to
submit for publication.
Results
Between 30 August 2004 and 31 December 2008, 432
patients potentially eligible for the trial were screened. As
many as 72 were excluded before randomisation. Fig. 1
shows the trial profile. Reasons for exclusion consisted
mainly in patients’ refusal (79.2%) and less commonly in
investigators’ choice (20.8%). Enrolment was stopped when
only 50% of the desired inclusion population was reached
after 3 years, based on futility analysis results. Fig. 2 shows
patients enrolment over time.
A total of 360 patients, who consented, were rando-
mised at 20 centres: 182 were assigned to undergo early
EVAR and 178 to undergo surveillance.
Figure 2 Patients’ enrolment over years.
16 P. Cao et al.There were 345 (95.8%) males and 15 (4.2%) females,
aged 50e79 years; and mean aneurysm diameter was
47.2 mm (SD 3.24). The two groups were similar at baseline
except for mean distal aortic diameter, which was about
1.5 mm smaller in the surveillance group (27.5 versus
29.0 mm) (Tables 1e3).
Of the 182 patients randomly assigned to early EVAR,
seven did not undergo endovascular repair after random-
isation: six declined treatment and one underwent open
repair according to patient’s choice. Overall, the treatment
was started according to the randomised assignment in
96.0% of patients (175 of 182).
Of the 178 patients assigned to surveillance, one
received immediate EVAR and the treatment started
according to randomised assignment in 99.4% of patients
(177 of 178).
Following the enrolment, of the aneurysms in the EVAR
group, four had open surgery, all according to protocol:
three because of immediate EVAR failure (immediate
conversion) and one was a late conversion. Of the aneu-
rysms under surveillance, 172 did not undergo repair until
the diameter of the AAA was more than 5.5 cm, increased
more than 1 cm/ year or became tender (per-protocol
repair). Five patients assigned to surveillance underwent
repair against the protocol: four requested early EVAR and
one had surgery performed by a surgeon not participating in
the trial.
Therefore, by the time of the present analysis (31 January
2010), 96.4% of patients overall adhered to their assigned
treatment (347 of 360). Aneurysm repair had been per-
formed overall in 175/182 of the patients in the early EVAR
group (171 EVAR and four open) and in 85/178 in the
surveillance group. Themedian time between randomisationFigure 1 Trand repair was 22 days (IQR 14e35) in the early EVAR group
and 741 days (IQR 443e937) in the surveillance group. Early-
EVAR resulted in significantly reduced mean procedure time
and mean estimated blood loss. Perioperative mortality (30
days or inpatient) and mean hospital stay were similar in the
two groups (Table 4).
Median follow-up was 32.4 months (IQR 21.0e44.1) in the
early EVARgroupand 30.9 (IQR18.3e45.3) in the surveillance
arm. A total of 313 patients had either completed 12 months
of follow-upor diedbefore, 168 completed36months’ and64
completed 54 months of follow-up.
There was no difference in all-cause mortality between
the two groups (HR 0.76; 95% CI 0.30e1.93; pZ 0.6) and at
54 months’ cumulative probability of mortality was 14.5% in
the early EVAR and 10.1% in the surveillance group (Fig. 3).ial profile.
Table 1 Risk factors and demographics at the time of randomisation.
Characteristics Total (n Z 360) EVAR (n Z 182) Surveillance (n Z 178) P value
Age, mean (SD) y 68.9(6.8) 69 (6.4) 68.8 (7.2) 0.73
Female gender, No. (%) 15(4.2) 9 (4.9) 6 (3.4) 0.62
Smoking, No. (%) 199(55.3) 105 (57.7) 94 (52.8) 0.40
Hypertension, No. (%) 271(75.3) 135 (74.2) 136 (76.4) 0.71
Hyperlipemia, No. (%) 225(62.5) 113 (62.1) 112 (62.9) 0.95
Cardiac disease, No. (%) 141(39.2) 66 (36.3) 75 (42.1) 0.30
Chronic obstructive pulmonary disease, No.(%) 102(28.3) 57 (31.3) 45 (25.3) 0.24
Diabetes, No. (%) 49(13.6) 29 (15.9) 20 (11.2) 0.25
Renal disease, No. (%) 29(8.1) 13 (7.1) 16 (9.0) 0.65
Serum creatinine, mean (SD) mg/dL 1.08(0.26) 1.07 (0.24) 1.09 (0.28) 0.34
Cerebrovascular disease, No. (%) 54(15%) 21 (11.5) 33 (18.5) 0.08
Peripheral artery disease, No. (%) 46(12.8) 17 (9.3) 29 (16.3) 0.06
Previous laparotomy, No. (%) 72(20) 35 (19.2) 37 (20.8) 0.81
BMI >31 Kg/m2, No. (%) 68(18.9) 35 (19.2) 33 (18.5) 0.97
Surgical risk (ASA score), No. (%) 0.85
ASA 1 44(12.2) 21 (11.5) 23 (12.9)
ASA 2 180(50.0) 90 (49.5) 90 (50.6)
ASA 3 136(37.8) 71 (39.0) 65 (36.5)
Risk factors definitions were based and graded according to the SVS standards.11
Surveillance Versus Endografting in small Aneurysms 17Aneurysm-related mortality was similar in the two
groups with one death occurring in each. In the early EVAR
group, one patient died due to fatal perioperative
pancreatitis while, in the surveillance group, there was one
fatal aneurysm rupture. Overall, two late ruptures occurred
(both in the surveillance group) in two aneurysms with 42.0
and 45.0 mm baseline diameter. At the time of rupture,
respectively at 24 and 52 months after randomisation, the
aneurysms were 56.0 and 55.0 mm in size and were both
already scheduled for repair after CT assessment. One
rupture was successfully treated by EVAR. Causes of late
mortality are shown in Table 5.Table 2 Morphological characteristics at the time of randomisa
Characteristic Total (n Z 36
AAA diameter, mm Mean (SD) 47.2(3.24)
N (%)
41e44 mm
45e49 mm
50e54 mm
Eurostar classification N (%)
A 120(33.3)
B 181(50.3)
C 42(11.7)
D 10(2.8)
E 7(1.9)
Distal aortic diameter, mean (SD) mm 28.2(6.7)
Aortic neck length, mean (SD) mm 27.9(12.5)
Aortic neck diameter, mean (SD) mm 22.7(2.5)
Aortic neck 15 mm below renals, mean (SD) mm 23.4(2.77)As many as 55 adverse events of any type occurred in 45
patients and were more frequent in the early EVAR group
compared with the surveillance group (Table 5). Estimated
cumulative probabilities of adverse event in early EVAR
versus surveillance patients were 19.8% versus 4.0% at 36
months and 21.2% versus 14.8% at 54 months (P < 0.001). As
many as 13 adverse events occurring in 11 patients were
major according to the SVS standard definitions12 and were
equally distributed between the two groups.
A total of 10 secondary therapeutic procedures (re-
interventions) were needed after early EVAR repair, and
none in the surveillance group (P Z 0.03); seven weretion.
0) EVAR (n Z 182) Surveillance (n Z 178) P value
47.5 (3.34) 47.0 (3.12) 0.14
N % N %
40 (22.0) 42 (23.6)
83 (45.6) 96 (53.9)
59 (32.4) 40 (22.5)
N % N % 0.33
53 (29.1) 67 (37.6)
97 (53.3) 84 (47.2)
23 (12.6) 19 (10.7)
4 (2.2) 6 (3.4)
5 (2.7) 2 (1.1)
29.0 (6.6) 27.5 (6.8) 0.04
28.1 (13.2) 27.6 (11.8) 0.69
22.8 (2.7) 22.5 (2.3) 0.19
23.6 (2.8) 23.3 (2.7) 0.45
Table 3 Medications at the time of randomisation.
Medications Total (n Z 360) EVAR (n Z 182) Surveillance (n Z 178) P value
N (%) N % N %
b eBlocker 81(24.8) 44 (26.0) 37 (23.6) 0.69
Aspirin 201(58.6) 102 (57.6) 99 (59.6) 0.78
ACE inhibitor 158(46.9) 70 (41.4) 88 (52.4) 0.06
Anticoagulants 19(5.9) 8 (4.8) 11 (7.1) 0.53
Diuretics 89(27.4) 47 (28.0) 42 (26.8) 0.90
Calcium channel Blocker 92(28.7) 52 (31.1) 40 (26.0) 0.36
Nitrates 29(9.2) 12 (7.4) 29 (9.2) 0.35
Statins 148(44.7) 76 (44.7) 72 (44.7) 1.00
Multiple drugs (3 or more) 85 (23.6) 44 (24.2) 41 (23.0) 0.98
18 P. Cao et al.associated with type II endoleak. Endoleak types and rates
are shown in Table 5. No migration or loss of graft integrity
occurred. Four open repairs were performed in the early
EVAR group; three were intraprocedural conversions while
the fourth was due to patient EVAR refusal.
Reasons for delayed repair in the surveillance group
included: n Z 75 aneurysm diameter achievement ofTable 4 Early outcome and operative findings in patients recei
EVAR
Operative findings
Time to repair, median
(IQR),days
22
Procedure duration, median
(IQR) min
100
Estimated blood loss, median
(IQR), mL
200
Hospital stay, median (IQR),
days
3
Early outcome Total EVAR
N
Mortality within 30 d or during
hospitalization, No (%)
1 1
Patients with 30 day any
morbidity related to repair,
No (%)
36 31/175
Patients with 30 day any major
morbidity, No (%)
10 6/175
Patients with 30 day device
related any morbidity, No (%)
3 3/175
Patients undergoing any repair,
No. (%)
260 175
Patients with open repair,
No (%)
18 4/175
Patients with 30 day any
morbidity related to repair,
No (%)a
Total EVAR (n Z 242
36 33
EVAR: Endovascular aortic aneurysm repair.
a 30 days morbidity events were reported from 260 patients with rep
patients in the surveillance group requiring delayed repair. P value w5.5 cm, nZ 20 aneurysm growth >1 cm/ year (in 11 asso-
ciated with achievement of 5.5 cm diameter), n Z 3
symptomatic aneurysm (in two associated with achievement
of5.5 cm, in one with rapid growth>1 cm/ year) and nZ 1
development of iliac aneurysm. Of the 85 patients in the
surveillance group undergoing delayed repair, 14 received
open repair because EVAR feasibility was lost according to CTving repair.
Surveillance P value
(1e593) 741 (443e937) <0.0001
(90e120) 117.5 (90e138.7) 0.0048
(100e300) 300 (150e500) 0.0023
(2e4) 3 (2e5) 0.1626
Surveillance P value
(%) N (%)
(0.6) 0 0 1.0
(17.7) 5/85 (6) 0.01
(3.4) 4/85 (4.7) 0.7
(1.7) e e 0.55
(96.2) 85 (47.8) <0.0001
(2.3) 14/85 (16) <0.0001
) Open repair (n Z 18) P value
(13.6) 3 (16.6) 0.722a
air and included 175 patients of the early EVAR group and the 85
as measured for EVAR versus open repair.
Figure 3 KaplaneMeier estimates of survival at 54 months from time of randomisation in EVAR versus Surveillance groups.
P Z 0.6. Numbers at risk are shown.
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The 36-month probability of receiving open repair for feasi-
bility loss was 16.4% and remained stable at 54 months.
KaplaneMeier estimates of aneurysm growth of 5 mm or
more (according to thefirst and last CTreadings) for the early
EVAR versus surveillance groups were 8.4% versus 67.5% at 36
months (HR 10.49; 95% CI 6.88e15.98; P < 0.01)(Fig. 4).
By linear regression models, aneurysm diameter
decreased at a mean rate of 3.15 mm/ year after EVAR. In
patients under surveillance, the initial enlarging diameter
was counterbalanced by a decreasing diameter in those
that were repaired resulting in a cumulative increase at
mean rate of 0.5 mm/ year. The mean increase of aneurysm
diameter in patients, who were never repaired at the time
of the analysis, was 1.5 mm/ year and in those before
receiving repair, 1.9 mm/ year.
In aneurysms under surveillance, estimated probability
of receiving delayed repair was 59.7% at 36 months and
84.5% at 54 months. At 36 months, the cumulative proba-
bility to have repair was 23.3% in aneurysms of 4.1e4.4 cm
diameter, 57.6% in those of 4.5e4.9 cm diameter, and
90.0% in those of 5.0e5.5 cm diameter (Fig. 5). After 54
months, the same probabilities were 76.1% for aneurysms
of 4.5e4.9 cm and 95.6% for aneurysms larger than 5.0 cm.
No valid information [standard error (SE) > 10%] was
available for the size category of 4.1e4.4 cm at 54 months.
The only significant positive predictors of delayed repair,
according to Cox regression analysis, were larger aneurysm
diameter (HR 1.27; 95% CI 1.18e1.37) and the absence of
hypertension under drug treatment (HR 0.7; 95% CI0.56e0.91). A trend towards positive association with
delayed repairwas foundalso for the absenceofdiabetes (HR
0.64; 95% CI 0.4e1.1) and of peripheral disease (HR 0.6; 95%
CI 0.35e1.06) that were retained in the final Cox model.Discussion
Two previous randomised trials on patients with small AAA
failed to detect a benefit in survival with early open repair
compared with surveillance.2,3,7,12 The UK Small Aneurysms
Trial (UKSAT), that randomly assigned 1090 patients with an
aneurysm of size comparable to those of the CAESAR
(4.0e5.5 cm) trial, demonstrated comparable long-term
survival rates between early repaired aneurysms and those
surveilled.2,12 Similarly, the CAESAR trial showed that after
54 months, all-cause mortality, aneurysm-related mortality
and major adverse event rates did not differ between
patients randomised to early EVAR and those randomised to
surveillance of AAA. However, the perioperative mortality
risk of repair by the endovascular approach (0.55%) was
significantly lower that that showed in the UKSAT with open
repair (5.8%),12 and aneurysm-related mortality rates after
54months were close to zero, confirming the safety of EVAR.
Nevertheless, the low risks of EVAR shown in the CAESAR
could not translate into a benefit over surveillance because
of similar safety shown with the surveillance strategy in
which rupture (and aneurysm-related mortality) events
were exceptional because only two ruptures occurred. The
estimates of all-cause mortality (14.5% versus 10.1%) and
Table 5 Late outcomes.
Outcomes Total EVAR (n Z 182) Surveillance (n Z 178) P value
Mortality after 30 d or
hospitalization
17 9 (4.9) 8 (4.5) 0.99
All-cause mortality (including
30-day), No (%)
18 10 (5.5) 8 (4.5) 0.80
Cause of death, No (%)
AAA related 2 1 (0.5) 1 (0.6)
Cardiovascular 6 4 (2.1) 2 (1.1)
Cancer 7 3 (1.6) 4 (2.2)
Other 1 1 (0.5) e
Unknown 2 1 (0.5) 1 (0.6)
Patients with any morbidity
(adverse event), No (%)
45 35 (19.1) 10 (5.1) <0.01
Cause of morbidity, No (%)
Atrial fibrillation 4 3 (1.6) 1 (0.6)
AAA rupture 2 e 2 (1.1)
Tender AAA 1 e 1 (0.6)
Aortic neck rupture 1 1 (0.5) e
Cardiovascular 3 2 (1.1) 1/85 (1.2)
Bleeding 10 8 (4.4) 2/85 (2.3)
Limb ischemia 7 6 (3.3) 1/85 (1.2)
Femoral or iliac dissection 2 2 (2.1) e
Blue toe syndrome 2 2 (2.1) e
Renal coverage/
embolization
8 7 (3.8) 1/85 (1.2)
Buttock ischemia/erectile
Dysfunction
4 4 (2.2) e
Wound infection 2 1 (0.5) 1/85 (1.2)
Other 9 6 (3.3) 3 (1.7)
Patients with any major
morbidity, No (%)
11 6 (3.3) 5 (2.8) 0.99
Conversion to open surgery
after EVAR (including 30
day), No (%)
4 4/175 (2.2) 0/71 e 0.32
Immediate conversion 3 (1.6) e e
Late conversion 1 (0.5) e e
Patients with secondary
Procedures (reintervention),
No (%)
10 10/175 (5.7) 0/85 e 0.03
Endoleak at 30 days, No (%) 35 28/175 (16) 7/71 (9.9) 0.23
Type I 2 1
Type II 25 4
Type III e 1
Unknown 1 1
Endoleak at 1 year, No (%) 23 21/175 (12) 2/71 (2.8) 0.028
Type I e e
Type II 19 2
Type IV 1 e
Unknown 1 e
Loss of device integrity e e e e e
Migration, No (%) e e e e e
EVAR: Endovascular aortic aneurysm repair.
20 P. Cao et al.aneurysm-related mortality (<1%) at 54 months in both arms
of the CAESAR trial were lower than those reported in
previous studies on small AAA,2,3 and mainly overlapped the
results recently shown by the only other randomised trial
that compared EVAR and surveillance on small AAA, the
Positive Impact of Endovascular Options for treatingAneurysms Early (PIVOTAL) trial.6 Like the CAESAR trial, the
PIVOTAL, that randomised 728 patients with 4.0e5.0 cm
aneurysms to early EVAR versus surveillance, found very low
mortality events: 4.1% mortality in each group after a mean
follow-up of 20 months, with 0.6% perioperative mortality
after EVAR. Authors were also surprised because of the
Table 6 Open repair in 14 patients assigned to surveillance.
Age Gender AAA at baseline
(mm)
AAA at repair
(mm)
Randomisation
date
Indication to
repair date
Morphology changes and
feasibility loss
1. 72 Male 52 57 5-12-2005 20-12-2006 Shortened aortic neck
(<10 mm)
2. 69 Male 52 57 5-3-2008 30-3-2009 Shortened aortic neck
(<10 mm)
3. 67 Male 43 50a 1-10-2004 24-10-2006 Neck dilatation; iliac
aneurysm
4. 50 Male 49 55 7-3-2006 11-2-2007 Contrast allergy new
onset
5. 67 Male 53.3 58.9 28-6-2006 30-1-2007 Neck thrombus; Funnel
shape
6. 66 Male 52 58 11-5-2005 5-7-2007 Not defined
7. 70 Male 50 57 11-2-2005 6-4-2006 Neck thrombus; Funnel
shape
8. 65 Male 48.4 55 5-5-2005 28-10-2005 Neck thrombus
9. 69 Male 48 55 19-1-2007 11-12-2008 Shortened aortic neck
(<10 mm)
10. 70 Male 49 56 2-2-2006 8-11-2007 Neck thrombus; Funnel
shape
11. 71 Male 5 57 10-2-2005 22-2-2007 Iliac access obstructive
disease
12. 69 Male 48 55 21-9-2004 16-12-2005 Shortened aortic neck;
neck angulation
13. 70 Female 45 55 24-7-2006 28-8-2008 Shortened aortic neck;
Inverted funnel shape
14. 65 Male 49 55 22-12-2006 12-11-2008 Shortened aortic neck;
neck dilatation
a Associated with iliac enlargement with iliac aneurysm development.
Surveillance Versus Endografting in small Aneurysms 21unexpectedly extremely low rupture risk: the 3-year risk of
aneurysm-related mortality was close to zero with only two
rupture occurring in both groups.
The CAESAR confirmed that rupture rate is very low in
small AAA and probably below the 1% annual rate published
before.1,2 Nevertheless, expansion, even in aneurysms of
small size, may be rapid and is associated with increased
rupture risk and loss of feasibility for EVAR in 16.4% of
patients at 36 months. The high rate of growth in small
AAAs may have important implications for safety during
surveillance and is a reason of concern in those patients
with small aneurysms that cannot be properly managed
under a strict surveillance programme. If an early EVAR
strategy is not applied, close surveillance is needed to
detect rapidly growing small aneurysms at increased
rupture risk. It has been indeed recently shown that, for
subjects with an AAA under surveillance, annual growth
rate of 2 mm is significantly associated with clinical
events.13
Surveillance provides a safe alternative method of
management of patients with aneurysms 4.1e5.4 cm but
requires to be based on accurate imaging and a careful
close monitoring. For the CAESAR study, yearly CT scan was
used to properly address any morphological change of the
aneurysms or the stent graft. This allowed obtaining very
low rupture and aneurysm-related death rates. Without
strict surveillance strategies, within rigorous trial proto-
cols, the same safe results are less likely to be reached.A strict surveillance strategy resulted in repair for 59.7%
of aneurysms under surveillance at 36 months and in 84.5%
at 54 months. Because about 60% of aneurysms grow to
require repair after less than 3 years, the option of antic-
ipated endovascular treatment with low operative risk
might be offered to selected patients with small AAA.
Anticipated repair might be a choice particularly for
patients with larger AAA size at baseline (>5.0 cm) as 90%
of these will undergo repair within 36 months. In addition,
from the CAESAR study, it was also remarkable that in
aneurysms of smaller size (4.5e4.9 cm diameter) under
surveillance estimates of repair at 36 months were as high
as 57.6%.
The strategy of surveillance raises the question of loss of
suitability for EVAR and the consequent increased proba-
bility to receive open repair.14,15
During the first 36 months of follow-up, 14 of 85 aneu-
rysms enrolled in the surveillance arm of the CAESAR trial
and requiring repair received open surgery because of loss
of feasibility for EVAR. According to KaplaneMeier esti-
mates, at 36 months, one over six patients under surveil-
lance will have changes in aneurysm morphology, mainly
related to changes in the proximal aortic neck, not allowing
delayed EVAR.
It has been suggested that best medical management,
such as the use of statins, can optimise and improve
natural history of patients under surveillance.16,17 In the
CAESAR trial, less than half the population (47.7%) was
Figure 4 KaplaneMeier estimates of aneurysm growth 5 mm at 36 months from time of randomisation in EVAR versus
Surveillance groups. P < 0.01. Numbers at risk are shown.
22 P. Cao et al.under statins medication and the trial could not prove or
disprove any advantage of these drugs. Nevertheless, 23%
of patients were takers of three or more drugs, mainly for
pressure control. Cox regression analysis suggested
a potential link between aneurysm growth requiring
repair and absence of history of diabetes, peripheral
disease and hypertension. While other studies also
confirmed the association between absence of diabetes
and an increased rate of aneurysm enlargement in small
AAA,3,18 the use of anti-hypertensive drugs might have
provided a protective effect on aneurysm growth from
high blood pressure in our ‘hypertensive’ patients.
However, our results might be affected by chance and
variable patient adherence to therapy. How the findings
of CAESAR may really influence the knowledge about the
natural history of aneurysm growth remains uncertain: it
could also be speculated that modification of athero-
sclerosis risk factors alone without repair may not
prevent aneurysm from enlargement.
The low mortality rate in the CAESAR trial may be
related to the experience of participating centres and to
the per-protocol inclusion criteria of patients without high
surgical risk, who would have benefited from early repair.
Of relevance, the rateof includedwomenwasparticularly
low (4.2%). It has been shown that the risk of rupture and the
likelihood of a poor outcome after rupture are greater in
women than in men.19,20 The findings of the CAESAR trial
could not be fit for a female population with small AAA.
The lack of difference in mortality risk between the two
arms of the CAESAR trial persisted despite the presence of a
higher number of adverse events and complications requiringsecondary procedure in the early EVAR arm. Indeed, most
adverse events wereminor in clinical relevance andmost re-
interventions were performed for type II endoleak correc-
tion. No migration or loss of device integrity occurred,
although follow-up length could not provide any strong
message in favour of or against all the last-generation
devices employed in the trial.
Limitations
The trial was stopped early and sample size was not ach-
ieved. We failed to prove the estimated difference in
mortality between EVAR and surveillance, but secondary
end points provided relevant information.
Furthermore, the length of follow-up was limited and
changed findings could be expected when longer follow-up
analyses will be achieved.7,21
This report intentionally lacks detailed information on
health-related quality of life analysis, which is ongoing.
In conclusion, mortality, aneurysm-related mortality and
rupture rates in small AAA are low and no advantage was
shown between early or delayed EVAR strategy. However,
three out of five small AAA may grow, quickly reaching
thresholds of high rupture and loss of EVAR suitability rates.
Surveillance with delayed EVAR does result in 60%
requirement of any repair and 16.4% of open repair after as
little as 36 months from initial evaluation. The relevant
aneurysm growth and need for repair rates in some small
AAAs require close and alert surveillance with scheduled CT
examination. Longer-term follow-up and detailed cost-
effectiveness assessment data are needed to fully assess
Figure 5 Part A: KaplaneMeier estimates of undergoing repair in the surveillance arm during 36 months follow-up. Part B:
KaplaneMeier estimates of undergoing repair in the surveillance arm during 36 months follow-up by baseline aneurysm diameter.
Surveillance Versus Endografting in small Aneurysms 23the relative merits of early EVAR versus surveillance strat-
egies in small AAA management.
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